Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Src inhibitors in suppression of papillary thyroid carcinoma growth.

Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL.

Head Neck. 2014 Mar;36(3):375-84. doi: 10.1002/hed.23316. Epub 2013 Jun 1.

2.

Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.

Henderson YC, Fredrick MJ, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2007 Aug;133(8):810-5.

PMID:
17709622
3.

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL.

Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29.

4.

Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.

Henderson YC, Ahn SH, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):347-54. doi: 10.1001/archoto.2009.17.

5.

Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.

Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH.

Cancer Biol Ther. 2011 Sep 1;12(5):458-65. Epub 2011 Sep 1.

PMID:
21725210
6.

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Henderson YC, Ahn SH, Kang Y, Clayman GL.

Clin Cancer Res. 2008 Aug 1;14(15):4908-4914. doi: 10.1158/1078-0432.CCR-07-1772.

7.

Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.

Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM.

Thyroid. 2010 Sep;20(9):965-74. doi: 10.1089/thy.2010.0008.

PMID:
20629553
8.

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE.

Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14.

9.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

10.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

11.
12.

RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.

Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M.

Mol Endocrinol. 2003 Jul;17(7):1382-94. Epub 2003 May 8.

PMID:
12738763
13.

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K.

Med Sci Monit. 2018 May 8 [revised 2018 Jan 1];24:3002-3010. doi: 10.12659/MSM.910084.

14.

Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.

Guerra A, Zeppa P, Bifulco M, Vitale M.

Thyroid. 2014 Feb;24(2):254-9. doi: 10.1089/thy.2013.0235. Epub 2013 Aug 24.

PMID:
23806056
15.

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR.

Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362.

16.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

17.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE.

Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.

18.

[The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].

Wang P, Wang YG, Zhao WJ, Fu YD, Wang L, Wang F, Zhao SH.

Zhonghua Nei Ke Za Zhi. 2012 Dec;51(12):987-91. Chinese.

PMID:
23327964
19.

The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.

Rusciano MR, Salzano M, Monaco S, Sapio MR, Illario M, De Falco V, Santoro M, Campiglia P, Pastore L, Fenzi G, Rossi G, Vitale M.

Endocr Relat Cancer. 2010 Jan 29;17(1):113-23. doi: 10.1677/ERC-09-0214. Print 2010 Mar.

PMID:
19903742
20.

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1600-9. doi: 10.1073/pnas.1404357111. Epub 2014 Apr 7.

Supplemental Content

Support Center